RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
ANNALS OF ONCOLOGY
Collezione ASL Asti

Items : 8

2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA) in Annals of Oncology

2024
ASL Asti

Giannatempo P; Polymeropoulos A; Stellato M; Ambrosini P; Gusmaroli E; Cavalli C; Guadalupi V; Claps M; Raggi D; Rametta A; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;

1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis in Annals of Oncology

2024
ASL Asti

Stellato M; Giannatempo P; Polymeropoulos A; Guadalupi V; Claps M; Ambrosini P; Raggi D; Rametta A; Cavalli C; Gusmaroli E; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;

1301P BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database in Annals of Oncology

2024
ASL Asti

Russo A; Sini C; Cortinovis DL; Muscarella LA; Perrone F; Bria E; Grisanti S; Piovano PL; Veccia A; Antonuzzo L; Citarella F; Belluomini L; Reale ML; Pignataro D; Roca E; Calvetti L; Passiglia F; Novello S; Baldini E;

2088P Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists in Annals of Oncology

2023
ASL Asti

Valsecchi AA; Fusco V; Di Maio M; Santini D; Tucci M; De Giorgi UFF; Dionisio R; Vignani F; Cinieri S;

1444P Cancer diagnosis communication: The perspective of oncologists, patients and caregivers in Annals of Oncology

2022
ASL Asti

Paratore C; Pacchiana Parravicini MV; Cantale O; Carfì F; Zichi C; Gamba T; Pignataro D; Samuelly A; Tucci M; Di Maio M; Novello S;

Evaluation of cognitive function (CogF) in trials testing new-generation hormonal treatments (NGHT) in patients with prostate cancer (PC): A systematic review in Annals of Oncology

2020
ASL Asti

Marandino L; Buttigliero C; Vignani F; Gamba T; Necchi A; Tucci M; Di Maio M;

From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial in Annals of Oncology

2020
ASL Asti

Garrone O; Giarratano T; Michelotti A; Saggia C; D'Onofrio L; Merlini L; Blondeaux E; Beano A; Coltelli L; Cazzaniga ME; Montemurro F; Farnesi A; La Verde NM; Vandone AM; Collovà E; Blasi L; Ardito R; DeConciliis E; Airoldi M; Merlano MC;

Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network in Annals of Oncology

2020
ASL Asti
ASL Biella

Berruti A; Mosca A; Bianchi S; Prati V; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Ciccone G; Sirotova Z; Chiappino I; Canton OD; Masini C; Sacco† C; Amoroso D; Montagnani F; Comandone A; Gennari A; Tucci M;